These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32860850)

  • 21. The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer.
    Masi I; Ottavi F; Del Rio D; Caprara V; Vastarelli C; Giannitelli SM; Fianco G; Mozetic P; Buttarelli M; Ferrandina G; Scambia G; Gallo D; Rainer A; Bagnato A; Spadaro F; Rosanò L
    Cell Death Dis; 2023 Jan; 14(1):73. PubMed ID: 36717550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling.
    Rosanò L; Cianfrocca R; Tocci P; Spinella F; Di Castro V; Spadaro F; Salvati E; Biroccio AM; Natali PG; Bagnato A
    Oncogene; 2013 Oct; 32(42):5066-77. PubMed ID: 23208497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells.
    Rosanò L; Spinella F; Di Castro V; Nicotra MR; Dedhar S; de Herreros AG; Natali PG; Bagnato A
    Cancer Res; 2005 Dec; 65(24):11649-57. PubMed ID: 16357176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition.
    Tocci P; Roman C; Sestito R; Di Castro V; Sacconi A; Molineris I; Paolini F; Carosi M; Tonon G; Blandino G; Bagnato A
    Cell Death Dis; 2023 Jan; 14(1):5. PubMed ID: 36604418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. β-arrestin1 at the cross-road of endothelin-1 signaling in cancer.
    Rosanò L; Bagnato A
    J Exp Clin Cancer Res; 2016 Jul; 35(1):121. PubMed ID: 27473335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis.
    Sestito R; Cianfrocca R; Rosanò L; Tocci P; Di Castro V; Caprara V; Bagnato A
    Life Sci; 2016 Aug; 159():43-48. PubMed ID: 26776834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methods to Investigate β-Arrestin-1/β-Catenin Signaling in Ovarian Cancer Cells.
    Rosanò L; Cianfrocca R; Bagnato A
    Methods Mol Biol; 2019; 1957():393-406. PubMed ID: 30919368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
    Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
    Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
    Bagnato A; Rosanò L
    Cells Tissues Organs; 2007; 185(1-3):85-94. PubMed ID: 17587812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The endothelin-1-driven tumor-stroma feed-forward loops in high-grade serous ovarian cancer.
    Tocci P; Roman C; Sestito R; Caprara V; Sacconi A; Molineris I; Tonon G; Blandino G; Bagnato A
    Clin Sci (Lond); 2024 Jul; 138(14):851-862. PubMed ID: 38884602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
    Cianfrocca R; Tocci P; Spinella F; Di Castro V; Bagnato A; Rosanò L
    Life Sci; 2012 Oct; 91(13-14):550-6. PubMed ID: 22480520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer.
    Rosanò L; Spinella F; Bagnato A
    Am J Physiol Regul Integr Comp Physiol; 2010 Aug; 299(2):R395-404. PubMed ID: 20538897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting YAP suppresses ovarian cancer progression through regulation of the PI3K/Akt/mTOR pathway.
    Wei X; Jia Y; Lou H; Ma J; Huang Q; Meng Y; Sun C; Yang Z; Li X; Xu S; Yang X; Ji T; Gao Q
    Oncol Rep; 2019 Dec; 42(6):2768-2776. PubMed ID: 31638241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells.
    Xia Y; Zhang YL; Yu C; Chang T; Fan HY
    PLoS One; 2014; 9(11):e109575. PubMed ID: 25369529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut-derived metabolite 3-methylxanthine enhances cisplatin-induced apoptosis via dopamine receptor D1 in a mouse model of ovarian cancer.
    Mai Z; Han Y; Liang D; Mai F; Zheng H; Li P; Li Y; Ma C; Chen Y; Li W; Zhang S; Feng Y; Chen X; Wang Y
    mSystems; 2024 Jul; 9(7):e0130123. PubMed ID: 38899930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
    de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
    Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Endothelin-1 Receptor/β-Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach.
    Tocci P; Rosanò L; Bagnato A
    Front Endocrinol (Lausanne); 2019; 10():609. PubMed ID: 31551935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
    Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
    Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
    Zhang Z; Qiu N; Yin J; Zhang J; Liu H; Guo W; Liu M; Liu T; Chen D; Luo K; Li H; He Z; Liu J; Zheng G
    Theranostics; 2020; 10(10):4290-4307. PubMed ID: 32292495
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.